CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 5,060 enrolled
Drug / intervention
Thinprep +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01131312
NCT01131312Phase 3Completed

Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)

National Cancer Institute (NCI)·interventional·Posted May 26, 2010·Updated Nov 20, 2018

In Brief

A Phase 3 clinical trial evaluating Thinprep, Hybrid capture 2, and 1 other intervention for Cervical Intraepithelial Neoplasia. Completed, enrolled 5,060 participants across 3 sites.

Detailed Summary

Approximately 65 million Pap smears are performed each year in the United States. The vast majority of results are negative (no abnormality identified) but about 5 percent to 8 percent are reported as abnormal. Most low-grade changes regress spontaneously; only a minority of such lesions would progress to a cancer precursor without treatment. However, there is no way to determine morphologically which patients are at risk or progression. Therefore, both high- and low-grade lesions were often managed with colposcopy and directed biopsy. Epidemiologic, virologic and molecular studies have clearly demonstrated that human papillomavirus (HPV) is the central cause of cervical cancer. The motivation for the Atypical squamous cells of undetermined significance (ASCUS)- Low grade squamous intraepithelial lesion (LSIL) Triage Study (ALTS) trial was to use the information we have gained about the role of HPV to design better treatment and prevention strategies to reduce the burden of cervical cancer and its precursors. ALTS consisted of three management strategies: (1) immediate colposcopy of all women; (2) repeat cytology with colposcopy only if the results show a high grade lesion; and (3) HPV testing and repeat cytology in combination, with referral to colposcopy if either the HPV test is positive or the cytology shows a high grade lesion. Four Clinical Centers University of Alabama, Birmingham Alabama (AL); Magee-Womens Hospital, Pittsburgh Pennsylvania (PA); University of Oklahoma, Oklahoma City OK; and University of Washington, Seattle Washington (WA) enrolled approximately 5,000 women with recent diagnosis of ASCUS or LSIL. Participants were followed at six month intervals for a total of 2 years. The ALTS database and ALTS specimens continue to be a valuable research resource in studies of cervical cancer precursors, screening tests, visual assessment of the cervix and investigation of biomarkers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 26, 2010
Enrollment StartFeb 20, 2008
Primary CompletionFeb 5, 2009
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 16.1 years ago

Interventions

Thinprepdevice

Pap test

Hybrid capture 2device

Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test

Colposcopyprocedure

Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.